Cambridge-based life sciences companies raised $173.9 million across four equity transactions over $1 million in Q3 2025, according to data compiled from Beauhurst and other public sources.

Mission Therapeutics in Cambridge has raised $13.3 million to progress clinical development of its lead candidate MTX325 through a Phase Ib proof-of-mechanism study in patients with Parkinson’s disease.

Investment in UK spinouts reached unprecedented levels in 2024, with a record £3.35 billion raised – up 44.3 per cent on the previous year. The boom is highlighted in a new report published today by Parkwalk Advisors, the UK’s most active investor in university spinouts, and analytics firm Beauhurst. It shows that equity investment in spinouts has significantly recovered from the dip seen in 2023.

Cambridge technology guru Steve Young has issued a heartfelt warning to AI giants not to overplay their hand and risk repeating the disastrous DotCom crash.